Of note, a single dose study showed that plasma PK parameters measured in the Abcd1 null mice were also within, or modestly below, exposure levels previously reported in a Phase 1B study where patients with nonalcoholic fatty liver were receiving 500 mg QD PXL770 (Fouqueray et al., 2021). Here, ABCD1 is linked to non-alcoholic fatty liver.